Hospital returns under drug diversion act
FDA is expected to issue a guidance letter by the end of the month. FDA will reportedly further liberalize an exemption for returns from the Prescription Drug Marketing Act's hospital resale ban. In a Nov. 3, 1988 guidance, the agency said hospital returns constitute banned resales unless the reason for returns are misshipment or misorder and they occur within 10 days of delivery.
You may also be interested in...
The addition of the question “Was this device serviced by a third party servicer?” to adverse event reports filed through the US FDA’s electronic Medical Device Reporting system could prove helpful for the agency and device makers, experts tell Medtech Insight. Industry has long complained about poor work performed by servicers – and loudly groused that they’re not regulated.
Attorneys tell Medtech Insight a recent proposal to review regulations every 10 years could lift some burdens from the medical device industry, but warned that the full effects may not be seen for some time.
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.